Surrogate endpoints need complementary patient reported outcomes

Cancer’s gold standard trial endpoint, overall survival (OS), is being overtaken by the growing use of surrogate endpoints. This presents regulators with challenges, but these are seldom debated in patient circles and we ignore the fact that surrogate endpoints focus on drug effect rather than patient benefit.

Read the source article at BMJ Blogs BMJ Blogs
2021-09-15 22:58:29